
A pile of money has been laid on the table belonging to the newly-founded biotech company Hemab, which develops pharmaceutical drugs against rare bleeding disorders for a market which is estimated to bring in billions of kroner.
Novo Seed has posted a million kroner figure in the double digits into Hemab, whose offices are located at the Copenhagen-based life science facility Cobis.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app